NetworkNewsAudio Announces Audio Press Release (APR) on Innovation in Cancer, Rare Disease Treatment Space [Video Edition]

AUSTIN, Texas, September 19, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies.

Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For further information, please visit the company’s website at www.Oncotelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictio